A small, light-activated molecule recently tested in mice represents a new approach to eliminating clumps of amyloid protein found in the brains of Alzheimer's disease patients. If perfected in humans, the technique could be used as an alternative approach to immunotherapy and used to treat other diseases caused by similar amyloids.
Researchers injected the molecule directly into the brains of live mice with Alzheimer's disease and then used a specialized probe to shine light into their brains for 30 minutes each day for one week. Chemical analysis of the mouse brain tissue showed that the treatment significantly reduced amyloid protein. Results from additional experiments using human brain samples donated by Alzheimer's disease patients supported the possibility of future use in humans.
"The importance of our study is developing this technique to target the amyloid protein to enhance clearance of it by the immune system," said Yukiko Hori, a lecturer at the University of Tokyo and co-first author of the research recently published in Brain.
The small molecule that the research team developed is known as a photo-oxygenation catalyst. It appears to treat Alzheimer's disease via a two-step process.
First, the catalyst destabilizes the amyloid plaques. Oxygenation, or adding oxygen atoms, can make a molecule unstable by changing the chemical bonds holding it together. Laundry detergents or other cleaners known as "oxygen bleach" use a similar chemical principle.
The catalyst is designed to target the folded structure of amyloid and likely works by cross-linking specific portions called histidine residues. The catalyst is inert until it is activated with near-infrared light, so in the future, researchers imagine that the catalyst could be delivered throughout the body by injection into the bloodstream and targeted to specific areas using light.
Second, the destabilized amyloid is then removed by microglia, immune cells of the brain that clear away damaged cells and debris outside healthy cells. Using mouse cells growing in a dish, researchers observed microglia engulfing oxygenated amyloid and then breaking it down in acidic compartments inside the cells.
"Our catalyst binds to the amyloid-specific structure, not to a unique genetic or amino acid sequence, so this same catalyst can be applied to other amyloid depositions," said Professor Taisuke Tomita, who led the project at the University of Tokyo.
The American Society of Clinical Oncology estimates that each year in the U.S., 4,000 people are diagnosed with diseases caused by amyloid outside of the brain, collectively known as amyloidosis. (https://www.cancer.net/cancer-types/amyloidosis/statistics)
The photo-oxygenation catalyst should be capable of removing amyloid protein, regardless of when or where it formed in the body. Although some existing Alzheimer's disease treatments can slow the formation of new amyloid plaques, eliminating existing plaques is especially important in Alzheimer's disease because amyloid begins aggregating years before symptoms appear.
The research team is now working to modify the design of the catalyst so it can be activated by shining light through the skull.
This research is a peer-reviewed experimental studying using mice and human tissue samples. Human temporal cortex brain samples used in this research came from the Alzheimer's Disease Core Center (ADCC) and the Center for Neurodegenerative Disease Research (CNDR) at the University of Pennsylvania in the U.S.
###
Research Publication
Shuta Ozawa, Yukiko Hori, Yusuke Shimizu, Atsuhiko Taniguchi, Takanobu Suzuki, Wenbo Wang, Yung Wen Chiu, Reiko Koike, Satoshi Yokoshima, Tohru Fukuyama, Sho Takatori, Youhei Sohma, Motomu Kanai, and Taisuke Tomita. 14 April 2021. Photo-oxygenation by a biocompatible catalyst reduces amyloid-β levels in Alzheimer's disease model. Brain. DOI:
10.1093/brain/awab058
https://doi.org/10.1093/brain/awab058
Related Links
Laboratory of Neuropathology and Neuroscience (in Japanese): http://www.f.u-tokyo.ac.jp/~neuropsc/tomita/
Graduate School of Pharmaceutical Sciences: http://www.f.u-tokyo.ac.jp/en/
Research Contact
Professor Taisuke Tomita
Laboratory of Neuropathology and Neuroscience, Graduate School of Pharmaceutical Sciences, The University of Tokyo, 153-8902, Tokyo, Japan.
Tel: +81-03-5841-4868
Email: taisuke@mol.fu-tokyo.ac.jp
Press Officer Contact
Ms. Caitlin Devor
Division for Strategic Public Relations, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 133-8654, JAPAN
Tel: +81-080-9707-8178
Email: press-releases.adm@gs.mail.u-tokyo.ac.jp
About the University of Tokyo
The University of Tokyo is Japan's leading university and one of the world's top research universities. The vast research output of some 6,000 researchers is published in the world's top journals across the arts and sciences. Our vibrant student body of around 15,000 undergraduate and 15,000 graduate students includes over 4,000 international students. Find out more at http://www.u-tokyo.ac.jp/en/ or follow us on Twitter at @UTokyo_News_en.
Funders
Japan Society for the Promotion of Science, Japan Agency for Medical Research and Development, Terumo Life Science Foundation
Journal
Brain